Justus G Garweg

List of Publications by Year
in descending order

65 papers	1,953 citations	361045 20 h-index	264894 42 g-index
70 all docs	70 docs citations	70 times ranked	1986 citing authors

#	Article	IF	Citations
1	Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study. Ocular Immunology and Inflammation, 2023, 31, 981-988.	1.0	2
2	Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series. Eye, 2022, 36, 862-868.	1.1	10
3	KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. American Journal of Ophthalmology, 2022, 238, 157-172.	1.7	77
4	Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. Advances in Therapy, 2022, 39, 2701-2716.	1.3	7
5	Pathophysiological Considerations in Periorbital Necrotizing Fasciitis: A Case Report. Ocular Immunology and Inflammation, 2022, , 1-6.	1.0	1
6	Outer retinal features in OCT predict visual recovery after primary macula-involving retinal detachment repair. PLoS ONE, 2022, 17, e0268028.	1.1	2
7	The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. International Journal of Molecular Sciences, 2022, 23, 7585.	1.8	19
8	Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD)Ââ€”Âa meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 2181-2192.	1.0	14
9	Treatment Strategy in Human Ocular Toxoplasmosis: Why Antibiotics Have Failed. Journal of Clinical Medicine, 2021, 10, 1090.	1.0	12
10	The double-edged role of internal limiting membrane peeling during primary rhegmatogenous retinal detachment repair. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 3191-3192.	1.0	2
11	Effect of Preoperative Intraocular Pressure in Patients with and without Intolerance to Their IOP-Lowering Medication on the Outcome of Trabectome Surgery. Clinical Ophthalmology, 2021, Volume 15, 1851-1860.	0.9	5
12	Visual Outcome after Intravitreal Anti-VEGF Therapy for Macular Neovascularisation Secondary to Sorsbyâ€™s Fundus Dystrophy: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 2433.	1.0	9
13	Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 3569-3578.	1.0	6
14	Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. Journal of Clinical Medicine, 2021, 10, 2666.	1.0	34
15	Ocular TGF-Î², Matrix Metalloproteinases, and TIMP-1 Increase with the Development and Progression of Diabetic Retinopathy in Type 2 Diabetes Mellitus. Mediators of Inflammation, 2021, 2021, 1-10.	1.4	13
16	Local and systemic gene expression levels of IL-10, IL-17 and TGF-Î² in active ocular toxoplasmosis in humans. Cytokine, 2021, 146, 155643.	1.4	6
17	Pitfalls in the Interpretation of Intraocular Inflammation in Response to Intravitreal Brolucizumab Injection. Ocular Immunology and Inflammation, 2021, , 1-3.	1.0	2
18	Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations. Scientific Reports, 2021, 11, 23989.	1.6	4

#	Article	IF	Citations
19	Reply. Retina, 2020, 40, e8-e10.	1.0	1
20	Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a caseâ€“control study. European Journal of Medical Research, 2020, 25, 59.	0.9	1
21	Risks and Challenges in Interpreting Simultaneous Analyses of Multiple Cytokines. Translational Vision Science and Technology, 2020, 9, 27.	1.1	10
22	Hybrid 23/27 Gauge Vitrectomy â€“ Combining the Charm of 27G with the Efficacy of 23G . Clinical Ophthalmology, 2020, Volume 14, 299-305.	0.9	4
23	Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration â€“ results from the randomized, phase IIIb OCTAVE study. BMC Ophthalmology, 2020, 20, 18.	0.6	8
24	Outcome of treatment for neovascular age-related macular degeneration by practice-based ophthalmologists compared with a macula clinic. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1405-1410.	1.0	1
25	Peripheral blood CD163(+) monocytes and soluble CD163 in dry and neovascular ageâ€related macular degeneration. FASEB Journal, 2020, 34, 8001-8011.	0.2	9
26	Impact of Vitreal Tamponade on Functional Outcomes in Vitrectomy with ILM Peeling in Primary Macula-Involving Retinal Detachment: A Retrospective Analysis. Clinical Ophthalmology, 2020, Volume 14, 4493-4500.	0.9	3
27	Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration . Clinical Ophthalmology, 2019, Volume 13, 1289-1295.	0.9	2
28	Choroidal Neovascularization Resulting from Angioid Streaks in Pseudoxanthoma Elasticum. Ophthalmology Retina, 2019, 3, 31.	1.2	0
29	Biomarkers for PVR in rhegmatogenous retinal detachment. PLoS ONE, 2019, 14, e0214674.	1.1	23
30	Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a â€œTreat-and-Extendâ€•Regimen. Ophthalmology Retina, 2019, 3, 393-399.	1.2	50
31	Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept. Ophthalmology Retina, 2019, 3, 567-575.	1.2	19
32	Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration . Clinical Ophthalmology, 2019, Volume 13, 2403-2409.	0.9	10
33	Cytokine profiles of phakic and pseudophakic eyes with primary retinal detachment. Acta Ophthalmologica, 2019, 97, e580-e588.	0.6	15
34	IMPACT OF INNER LIMITING MEMBRANE PEELING ON VISUAL RECOVERY AFTER VITRECTOMY FOR PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT INVOLVING THE FOVEA. Retina, 2019, 39, 853-859.	1.0	21
35	The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 823-831.	1.0	22
36	Cytokine profiles in the aqueous humor and serum of patients with dry and treated wet age-related macular degeneration. PLoS ONE, 2018, 13, e0203337.	1.1	40

#	Article	IF	Citations
37	Past and prognosis of anti-VEGF therapy for wet age-related macular degenerationâ€"the future has begun. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1553-1555.	1.0	2
38	Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective. Ocular Immunology and Inflammation, 2018, 26, 1135-1142.	1.0	17
39	Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 567-572.	0.6	11
40	Early Response to Ranibizumab Is Predictive of Treatment Demand after a Therapeutic Switch to Aflibercept. Ophthalmology Retina, 2017, 1, 210-216.	1.2	2
41	Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 773-778.	0.6	10
42	Isoforms of TGF-Î² in the aqueous humor of patients with pseudoexfoliation syndrome and a possible association with the long-term stability of the capsular bag after cataract surgery. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1763-1769.	1.0	20
43	Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma. PLoS ONE, 2017, 12, e0182571.	1.1	35
44	Pre-Existing RPE Atrophy and Defects in the External Limiting Membrane Predict Early Poor Visual Response to Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 326-332.	0.4	9
45	Vitreal Cytokine Profile Differences Between Eyes With Epiretinal Membranes or Macular Holes. , 2016, 57, 6320.		33
46	Impact of treatment on long-term visual function in retinal vein occlusionâ€"response to the comment on: retinal vein occlusion and the use of a dexamethasone intravitreal implant (OzurdexÂ®) in its treatment. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 2479-2480.	1.0	0
47	Retinal vein occlusion and the use of a dexamethasone intravitreal implant (OzurdexÂ®) in its treatment. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1257-1265.	1.0	47
48	Therapy for Ocular Toxoplasmosis â€“ The Future. Ocular Immunology and Inflammation, 2013, 21, 300-305.	1.0	24
49	Pathophysiology of Proliferative Vitreoretinopathy in Retinal Detachment. Survey of Ophthalmology, 2013, 58, 321-329.	1.7	129
50	Diagnostic Approach to Ocular Toxoplasmosis. Ocular Immunology and Inflammation, 2011, 19, 255-261.	1.0	87
51	Controversies in Ocular Toxoplasmosis. Ocular Immunology and Inflammation, 2011, 19, 2-9.	1.0	57
52	Anti-retinal autoantibodies in experimental ocular and systemic toxoplasmosis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 573-584.	1.0	9
53	Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study). Diabetes Care, 2010, 33, 2399-2405.	4.3	656
54	Immunopathology in ocular toxoplasmosis: facts and clues. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 211-220.	0.8	45

#	Article	IF	Citations
55	Outcome indicators for vitrectomy in Terson syndrome. Acta Ophthalmologica, 2009, 87, 222-226.	0.6	59
56	Clinical and laboratory diagnosis of ocular toxoplasmosis. Expert Review of Ophthalmology, 2008, 3, 333-346.	0.3	2
57	Visual function in human ocular toxoplasmosis. British Journal of Ophthalmology, 2007, 91, 233-236.	2.1	30
58	Effects of daunorubicin, mitomycinÂC, azathioprine and cyclosporinÂA on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 382-389.	1.0	30
59	The antibody response in experimental ocular toxoplasmosis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 1668-1679.	1.0	18
60	Reactivation of ocular toxoplasmosis during pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 241-242.	1.1	70
61	Specific antibody levels in the aqueous humor and serum of two distinct populations of patients with ocular toxoplasmosis. International Journal of Medical Microbiology, 2005, 295, 287-295.	1.5	15
62	Aqueous Humor and Serum Immunoblotting for Immunoglobulin Types G, A, M, and E in Cases of Human Ocular Toxoplasmosis. Journal of Clinical Microbiology, 2004, 42, 4593-4598.	1.8	43
63	HSV-1 antigens and DNA in the corneal explant buttons of patients with non-herpetic or clinically atypical herpetic stromal keratitis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2003, 241, 734-739.	1.0	7
64	Low rate shedding of HSV-1 DNA, but not of infectious virus from human donor corneae into culture media. , 1997, 52, 320-325.		17
65	Functional Outcome After Macular Hole Surgery: Comparison of Standard Perimetry with Microperimetry. Clinical Ophthalmology, 0, Volume 16, 2235-2243.	0.9	1